Mpox Vaccine Antibody Responses Waned Within a Year, Study Shows

UC Irvine Receives Initial $33 Million in Federal Support for Vaccine Research

Among People with HIV, Mpox Vaccine Protects Well

Grant Supports Vaccine Development to Protect Fetus from Cytomegalovirus

Link Type
Funded-research
Media Type
Article
Publish or Event Date
Link URL
https://news.weill.cornell.edu/news/2024/09/grant-supports-vaccine-development-to-protect-fetus-from-cytomegalovirus
Research Institution
Weill Cornell Medicine
Short Title
Grant Supports Vaccine Development to Protect Fetus from Cytomegalovirus
Content Coordinator
Claudia Wair
Content Manager
Jennifer Routh

AI Enlisted to Design Vaccines Against Pandemic Threats

$12 Million Grant Aimed at Probing How Vaccines Induce Lasting Immunity

Link Type
Funded-research
Media Type
Article
Publish or Event Date
Link URL
https://medicine.washu.edu/news/12-million-grant-aimed-at-probing-how-vaccines-induce-lasting-immunity/
Research Institution
Washington University School of Medicine in St. Louis
Short Title
$12 Million Grant Aimed at Probing How Vaccines Induce Lasting Immunity
Content Coordinator
Claudia Wair
Content Manager
Jennifer Routh

Trial of an Inactivated Chikungunya Virus Vaccine

The primary objective of this trial is to evaluate dosages and assess the safety and reactogenicity of the HydroVax-005 CHIKV vaccine.

Contact Information

Office/Contact: Lynn S Harrington, RN, BSN, CCRP
Phone: 919-620-5353
Email: lynn.harrington@duke.edu
 

Viral Infections in Healthy and Immunocompromised Hosts

The objective of this study is to collect samples and data from individuals who have been exposed to or have contracted viral infections.

Sample Collection for Systems Evaluation of Patients With Unknown or Incompletely Characterized Immune Defects

Researchers want to study samples from people with healthy immune systems and people with conditions that affect how the immune system works to learn more about the immune system and how immunological disorders predispose affected individuals to a myriad of complications, including infection, immune dysregulation with autoimmune disease and aberrant inflammatory responses, and malignancy.

Contact Information

Office/Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)
Phone: 800-411-1222
TTY: TTY8664111010
Email: prpl@cc.nih.gov
 

A Novel Vaccine and Therapeutic for Hendra and Nipah Viruses

NIAID-funded researchers at the Uniformed Services University of the Health Sciences (USU) and their collaborators at the National Cancer Institute discovered a potential antibody treatment for Nipah and Hendra virus. The researchers developed a human monoclonal antibody (mAb) known as m102.4 that targets the G glycoprotein of both viruses and found that the mAb effectively protected ferrets after exposure to Nipah or Hendra virus. The mAb was also effective in protecting nonhuman primates after exposure.
Subscribe to Vaccines